

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No. 2503-A

Cindy A. Jacobs and Craig A. Smith

Group Art Unit: 1806

Serial No.:

08/385,229

Examiner:

Nisbet, T.

Filing Date:

February 8, 1995

For:

METHOD OF TREATING TNF-DEPENDENT INFLAMMATION USING

TUMOR NECROSIS FACTOR ANTAGONISTS

Commissioner of Patents and Trademarrks Washington, D.C. 20231

AMENDMENT

Sir:

In response to the Office Action dated November 24, 1995 in connection with the above-identified application, please make the following amendments.

In the Claims:

Cancel claims 1, 2, 4, 5, 6, 8 and 9.

Add the following new claims:

- 10. (New) A method for inhibiting TNF-α activity in a mammal in need thereof which comprises administering to said mammal a TNF-binding amount of a TNF antagonist selected from the group consisting of:
- (a) a Type I TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1;
 - (b) the extracellular domain of a Type If TNF receptor;
- (c) a chimeric antibody comprising a Type I TNF receptor according to (a) fused to the constant domain of an immunoglobulin molecule; and
- (d) a chimeric antibody comprising a Type II TNF receptor according to (b) fused to the constant domain of an immunoglobulin molecule.
- 11. (New) A method for treating arthritis in a mammal, comprising the step of administering to such mammal a therapeutically effective amount of a TNF-antagonist selected from the group consisting of:

B